エンパグリフロジン、ダパグリフロジン、カナグリフロジンの世界市場レポート 2025年

エンパグリフロジン、ダパグリフロジン、カナグリフロジンの市場規模は、今後数年間で安定した成長が見込まれます。2029年の年間平均成長率（CAGR）は2.7%で、110億6,000万米ドルに成長します。予測期間における成長の背景には、経口糖尿病治療薬に対する需要の増加、糖尿病研究開発への投資の増加、ヘルスケア支出の増加、糖尿病予備軍に対する認識と診断の高まり、併用療法への注目の高まりなどがあります。予測期間における主な動向には、技術の進歩、併用療法、遠隔医療、健康データ分析、患者データのセキュリティなどがあります。

糖尿病の有病率の増加は、エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場の拡大を促進すると予想されます。糖尿病は、インスリン分泌不足またはインスリンを効果的に使用できない体質による高血糖を特徴とする慢性的な健康状態です。糖尿病患者の増加は、座りがちなライフスタイル、食生活の乱れ、遺伝的要因、都市化、高齢化、ヘルスケアへのアクセスの制限、世界の肥満率の増加など、さまざまな要因に起因しています。エンパグリフロジン、ダパグリフロジン、カナグリフロジンは、腎臓のナトリウム-グルコース共輸送体-2（SGLT2）を阻害することにより血糖値を下げ、尿によるグルコース排泄を促進することで糖尿病を管理するために使用されます。例えば、2024年6月、国民保健サービス（NHS）は、40歳未満の糖尿病患者が急増し、2022年の17万3,166人から2023年には21万6,440人に増加したと報告しました。この急激な増加は、若年層における懸念すべき動向を浮き彫りにしています。その結果、糖尿病有病率の増加がエンパグリフロジン、ダパグリフロジン、カナグリフロジンの市場成長に拍車をかけています。

エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場の主要企業は、より幅広い患者層に対応し、市場での存在感を高めるため、小児2型糖尿病治療薬などの革新的な製品の創出に注力しています。小児2型糖尿病治療には、生活習慣の改善、薬物療法、時には小児や青年向けに特別にデザインされたインスリン療法による血糖管理が含まれます。例えば、2024年6月、英国の製薬会社アストラゼネカは、10歳以上の小児2型糖尿病患者の血糖コントロールを改善するファルキシガ（ダパグリフロジン）の承認を米国食品医薬品局（FDA）から取得しました。今回の承認は、小児2型糖尿病患者を対象とした最大規模の臨床試験の1つであるT2NOW第III相試験において、ファルキシガがプラセボと比較してHbA1c値を有意に低下させるという良好な結果が得られたことを受けたものです。この年齢層におけるファルキシガの安全性プロファイルは、成人の2型糖尿病患者におけるプロファイルと一致していました。小児の2型糖尿病に対する経口治療の選択肢は乏しかったため、このマイルストーンは重要であり、心血管疾患、腎疾患、代謝性疾患の治療法の進歩に対するアストラゼネカの献身的な取り組みを浮き彫りにするものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界エンパグリフロジン、ダパグリフロジン、カナグリフロジンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：成長率分析
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場の実績：規模と成長, 2019-2024
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場の予測：規模と成長, 2024-2029, 2034F
• 世界エンパグリフロジン、ダパグリフロジン、カナグリフロジン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンパグリフロジン
• ダパグリフロジン
• カナグリフロジン
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アプリケーションI
• アプリケーションII
• アプリケーションIII
• アプリケーションIV
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 薬局
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場エンパグリフロジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 10mg
• 25mg
• 50mg
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場ダパグリフロジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5mg
• 10mg
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場カナグリフロジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 100mg
• 300mg

第7章 地域別・国別分析

• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のエンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：競合情勢
• エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc（GSK）
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• MSN Laboratories Private Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Cipla Limited
• Cadila Healthcare Limited
• Apotex Inc.
• Lupin Limited
• Biocon Limited
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場2029：新たな機会を提供する国
• エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場2029：新たな機会を提供するセグメント
• エンパグリフロジン、ダパグリフロジン、カナグリフロジン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Empagliflozin, dapagliflozin, and canagliflozin are medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, primarily prescribed for managing type 2 diabetes mellitus. These oral medications are part of a comprehensive diabetes treatment plan that also involves diet, exercise, and potentially other medications.

The specific types of these SGLT-2 inhibitors include empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is used mainly to reduce blood sugar levels in adults with type 2 diabetes by aiding the kidneys in expelling glucose through urine. These medications are available in various applications, including application I, application II, application III, and application IV, and can be purchased through hospitals and pharmacies.

The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports from The Business Research Company that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with an empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends, and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.

The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.06 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to increasing demand for oral diabetes medications, increasing investments in diabetes research and drug development, increasing healthcare expenditure, rising awareness and diagnosis of pre-diabetes conditions, and increasing focus on combination therapies. Major trends in the forecast period include technological advancements, combination therapies, telehealth, health data analytics, and patient data security.

The growing prevalence of diabetes is expected to drive the expansion of the empagliflozin, dapagliflozin, and canagliflozin market. Diabetes is a chronic health condition characterized by high blood sugar levels due to insufficient insulin production or the body's inability to use insulin effectively. The rise in diabetes cases can be attributed to various factors, including sedentary lifestyles, poor dietary choices, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Empagliflozin, dapagliflozin, and canagliflozin are used to manage diabetes by lowering blood sugar levels through the inhibition of sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urine. For example, in June 2024, the National Health Service (NHS) reported a sharp increase in diabetes cases among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This rapid rise underscores a concerning trend in the younger population. As a result, the growing prevalence of diabetes is fueling the market growth for empagliflozin, dapagliflozin, and canagliflozin.

Key players in the empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on creating innovative products, such as treatments for pediatric type-2 diabetes, to cater to a wider patient base and enhance their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar through lifestyle modifications, medications, and occasionally insulin therapy specifically designed for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 and older with type 2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies, demonstrating that Farxiga significantly reduced HbA1c levels compared to a placebo. The safety profile of Farxiga in this age group was consistent with its profile in adults with type 2 diabetes. This milestone is significant as oral treatment options for pediatric type-2 diabetes have been scarce, highlighting AstraZeneca's dedication to advancing treatments for cardiovascular, renal, and metabolic diseases.

In March 2024, Nirma Limited, an India-based company in the chemical industry specializing in manufacturing, retailing, and distributing commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for $682 million, the amount undisclosed. Through this acquisition, Nirma Limited aims to strengthen its foothold in the pharmaceutical sector, diversify its product portfolio, and leverage research and development capabilities to drive sustainable long-term growth. Glenmark Life Sciences, an India-based pharmaceutical company, manufactures active pharmaceutical ingredients (APIs) for empagliflozin, dapagliflozin, and canagliflozin, which are used in diabetes treatment production.

Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.

North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on empagliflozin, dapagliflozin and canagliflozin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for empagliflozin, dapagliflozin and canagliflozin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The empagliflozin, dapagliflozin and canagliflozin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin
• 2) By Application: Application I; Application II; Application III; Application IV
• 3) By Channel: Hospital; Pharmacy
• Subsegments:
• 1) Empagliflozin: 10 Mg; 25 Mg; 50 Mg
• 2) Dapagliflozin: 5 Mg; 10 Mg
• 3) Canagliflozin: 100 Mg; 300 Mg
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Empagliflozin, Dapagliflozin And Canagliflozin Market Characteristics

3. Empagliflozin, Dapagliflozin And Canagliflozin Market Trends And Strategies

4. Empagliflozin, Dapagliflozin And Canagliflozin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Empagliflozin, Dapagliflozin And Canagliflozin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Empagliflozin, Dapagliflozin And Canagliflozin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Growth Rate Analysis
• 5.4. Global Empagliflozin, Dapagliflozin And Canagliflozin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Empagliflozin, Dapagliflozin And Canagliflozin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Empagliflozin, Dapagliflozin And Canagliflozin Total Addressable Market (TAM)

6. Empagliflozin, Dapagliflozin And Canagliflozin Market Segmentation

• 6.1. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Empagliflozin
• Dapagliflozin
• Canagliflozin
• 6.2. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Application I
• Application II
• Application III
• Application IV
• 6.3. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Pharmacy
• 6.4. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Sub-Segmentation Of Empagliflozin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10 Mg
• 25 Mg
• 50 Mg
• 6.5. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Sub-Segmentation Of Dapagliflozin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5 Mg
• 10 Mg
• 6.6. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Sub-Segmentation Of Canagliflozin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100 Mg
• 300 Mg

7. Empagliflozin, Dapagliflozin And Canagliflozin Market Regional And Country Analysis

• 7.1. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Empagliflozin, Dapagliflozin And Canagliflozin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market

• 8.1. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Empagliflozin, Dapagliflozin And Canagliflozin Market

• 9.1. China Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 9.2. China Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Empagliflozin, Dapagliflozin And Canagliflozin Market

• 10.1. India Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market

• 11.1. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 11.2. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market

• 12.1. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market

• 13.1. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market

• 14.1. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 14.2. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market

• 15.1. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 15.2. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Empagliflozin, Dapagliflozin And Canagliflozin Market

• 16.1. UK Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market

• 17.1. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Empagliflozin, Dapagliflozin And Canagliflozin Market

• 18.1. France Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market

• 19.1. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market

• 20.1. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market

• 21.1. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 21.2. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market

• 22.1. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Empagliflozin, Dapagliflozin And Canagliflozin Market

• 23.1. North America Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 23.2. North America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Empagliflozin, Dapagliflozin And Canagliflozin Market

• 24.1. USA Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 24.2. USA Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market

• 25.1. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 25.2. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Empagliflozin, Dapagliflozin And Canagliflozin Market

• 26.1. South America Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 26.2. South America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market

• 27.1. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market

• 28.1. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 28.2. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market

• 29.1. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market Overview
• 29.2. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market, Segmentation By Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Landscape And Company Profiles

• 30.1. Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Landscape
• 30.2. Empagliflozin, Dapagliflozin And Canagliflozin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Empagliflozin, Dapagliflozin And Canagliflozin Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc (GSK)
• 31.2. Eli Lilly and Company
• 31.3. Boehringer Ingelheim GmbH
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. MSN Laboratories Private Limited
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Aurobindo Pharma Limited
• 31.9. Cipla Limited
• 31.10. Cadila Healthcare Limited
• 31.11. Apotex Inc.
• 31.12. Lupin Limited
• 31.13. Biocon Limited
• 31.14. Alkem Laboratories Ltd.
• 31.15. Torrent Pharmaceuticals Ltd.

32. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Empagliflozin, Dapagliflozin And Canagliflozin Market

34. Recent Developments In The Empagliflozin, Dapagliflozin And Canagliflozin Market

35. Empagliflozin, Dapagliflozin And Canagliflozin Market High Potential Countries, Segments and Strategies

• 35.1 Empagliflozin, Dapagliflozin And Canagliflozin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Empagliflozin, Dapagliflozin And Canagliflozin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Empagliflozin, Dapagliflozin And Canagliflozin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer